triple acting glp 1 Retatrutide is one of the most exciting medications currently being studied for obesity and metabolic disease-but there's one important thing to understand: It is NOT approved yet. I get asked almost daily, “ GLP-1-based therapies for type 2

Employers are accelerating their ability to be their own insurance company through self-funding their employee benefits. LOUISVILLE , KY, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- As major insurers across the U.S

PMID: 34017637

Standardized study designs, consistent reporting methods, and better control of lifestyle and dietary variables are crucial to deepen our understanding of these interactions

FDA, on February 3, 2012 Healthy People Co

Romanek, R

See IRS Publication 502 for more information: Final Note: According to the Washington Post, Americans spent in 2024 approximately $40 billion on GLP-1 medications